Live Breaking News & Updates on Davide melisi

Stay informed with the latest breaking news from Davide melisi on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Davide melisi and stay connected to the pulse of your community

NALIRIFOX Prolongs Survival With a Tolerable Safety Profile in mPDAC

Davide Melisi, MD, PhD, discusses the potential of NALIRIFOX as a new first-line standard of care for patients with metastatic pancreatic ductal adenocarcinoma, noting that pending FDA approval, this effective and tolerable regimen could also inform future clinical trials designs for patients with pancreatic cancer.

Italy , Davide-melisi , Department-of-medicine , University-of-verona , D , Hd , Nalirifox , Pancreatic-cancer , Metastatic-pancreatic-ductal-adenocarcinoma , Irinotecan-liposome-injection-plus-5-fluorouracil , Eucovorin , Nd-oxaliplatin

New research highlights potential of iOnctura strategy combining autotaxin and TGF-ß inhibitors in cancer

New research highlights potential of iOnctura strategy combining autotaxin and TGF-ß inhibitors in cancer
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Netherlands , Switzerland , Amsterdam , Noord-holland , Geneva , Genè , Swiss , Davide-melisi , Catherine-pickering , Indiens-wirtschaft , Ihre-chancen , University-of-verona

New research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer

/PRNewswire/ -- iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival...

Amsterdam , Noord-holland , Netherlands , Geneva , Genè , Switzerland , Swiss , Catherine-pickering , Davide-melisi , University-of-verona , B-future-health-fund , Cancer-research

iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289

Geneva, Switzerland, 8 December 2022 -- iOnctura SA a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumor survival pathways, announces

Geneva , Genè , Switzerland , Italy , United-states , United-kingdom , David-brindley , Chris-maggos , Jeff-evans , Michele-maio , Davide-melisi , Kostenloser-wertpapierhandel